Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...